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Background and purpose: A reduced cancer risk amongst patients with
multiple sclerosis (MS) has been reported. Theoretically, this could represent a
genuine reduction in risk or, alternatively, ‘diagnostic neglect’, where cancer is
undiagnosed when symptoms are misattributed to MS.
Objective: Assess all-cause mortality risk following a cancer diagnosis in
patients with MS compared with a cohort without MS.
Patients: A cohort of MS patients (n = 19 364) and a cohort of the general
population (n = 192 519) were extracted from national Swedish registers from
1969 to 2005. All-cause mortality after cancer in MS was compared with the
general population. Poisson regression analysis was conducted in the MS and
non-MS cohorts separately. The models were adjusted for follow-up duration,
year at entry, sex, region and socioeconomic index. The two cohorts were
combined and diﬀerences in mortality risk were assessed using interaction test-
ing.
Results: The adjusted relative risk (and 95% conﬁdence interval) for all-cause
mortality following a cancer diagnosis in MS patients (compared with MS
patients without cancer) is 3.06 (2.86–3.27; n = 1768) and amongst those with-
out MS 5.73 (5.62–5.85; n = 24 965). This lower magnitude mortality risk in
the MS patients was conﬁrmed by multiplicative interaction testing
(P < 0.001).
Conclusions: A consistent pattern of lower magnitude of all-cause mortality
risk following cancer in MS patients for a range of organ-speciﬁc cancer types
was found. It suggests that cancer diagnoses tend not to be delayed in MS
and diagnostic neglect is unlikely to account for the reduced cancer risk asso-
ciated with MS. The lower magnitude cancer risk in MS may be due to dis-
ease-associated characteristics or exposures.
Introduction
There appears to be a reduced cancer risk amongst
patients with multiple sclerosis (MS) [1–3], but
whether this is a genuine reduction in risk has not
been completely resolved. One possibility is that
symptoms of cancer are misinterpreted as those of
MS, resulting in failure to identify the cancer and thus
‘diagnostic neglect’ [3]. This would lead to under-diag-
nosis of cancer or at least a delay in its diagnosis.
Such a delay would be likely to result in higher cancer
mortality consistent with diagnostic neglect [3]. An
assessment of mortality following cancer will help to
resolve the extent to which cancer diagnoses are
delayed in MS patients and whether there is a genuine
reduction in cancer risk.
Correspondence: H. Roshanisefat, Department of Neurology,
Karolinska University Hospital Huddinge, 14186 Stockholm,
Sweden (tel.: +46 8 58580000; fax: +46 8 774 48 22; e-mail:
Homayoun.Roshanisefat@karolinska.se).
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Previous studies of survival following cancer in MS
patients have yielded inconsistent results, with risks
for mortality that are increased [4,5] or decreased
[6–8] or with no diﬀerence compared with the general
population [9]. One diﬃculty in comparing mortality
in MS patients with the general population is that MS
in itself is associated with a notable reduction in life
span by approximately 5–10 years [10]. This is one
reason why use of cancer-speciﬁc mortality can be
problematic, as MS-related mortality may represent a
competing risk for cancer mortality. All-cause mortal-
ity has been described as an important marker of MS
outcome and encompasses many aspects of disease
progression [11]. Therefore, all-cause mortality follow-
ing a cancer diagnosis was examined but using inter-
action testing to take into account average diﬀerences
in life span amongst those with MS and a general
population cohort. This is also important, as the asso-
ciation of cancer with all-cause mortality in MS
patients is likely to be of lower magnitude than in the
general population as other causes are more likely.
Another issue is that patients with MS have a dif-
ferent case mix for cancer compared with the general
population, so examination of risk for organ-speciﬁc
cancers as well as all cancers is important. An exam-
ple of this is brain tumours, which unlike other cancer
types appear to be overrepresented in MS patients
[12]. In a previous study using the same material, it
was found that brain tumours were diagnosed at an
earlier age in MS patients and mortality was no worse
than amongst the general population [12]. The conclu-
sion was that this is because of more frequent imaging
in MS patients resulting in a greater detection of
tumours at an earlier stage, including those that are
asymptomatic. Brain tumours are only included in
overall risk estimation in this paper.
This study utilizes a cohort of Swedish MS patients
and a matched general population cohort, where all-
cause mortality risk following a primary cancer diag-
nosis is examined, taking overall mortality risk into
account through interaction testing. In addition to
addressing the issue of potential diagnostic neglect,
this study provides more general information on can-
cer prognosis in MS patients.
Patients and methods
Data sources and identification of multiple sclerosis
and general population cohorts
All subjects included in this study were drawn from
national Swedish registers, which have been described
previously [1,12,13]. Brieﬂy, patients who received a
diagnosis of MS in Sweden between 1969 and 2005
were identiﬁed through two complementary sources:
the National Patient Register and the Swedish Multi-
ple Sclerosis Register (SMSreg). The National Patient
Register recorded hospital discharge diagnoses since
1964 with national coverage since 1987 [14]. The
SMSreg contains clinical and demographic details for
patients with MS, including information that can be
used to conﬁrm the accuracy of an MS diagnosis [1].
The SMSreg requires written informed consent for
inclusion.
Patients with MS were individually matched with
up to 12 individuals (a lower number was achieved in
a minority of cases) from the general population with-
out MS by date of birth, sex, region and vital status
at the time of diagnosis.
Identification of cancer diagnosis
Through the Swedish Cancer Register, details of can-
cer diagnoses were identiﬁed (see Appendix). This reg-
ister was established in 1958 and records all newly
diagnosed malignant tumours in Sweden. The com-
pleteness of the Swedish Cancer Register is high, and
underreporting of cases is estimated to be <4% [15].
Diﬀerent editions of the International Classiﬁcation of
Diseases (ICD) have been used in the registry but all
are concerted to ICD-7 (Index 1). The region of resi-
dence was deﬁned in terms of the catchment areas of
the six regional cancer centres Stockholm, Malm€o,
Gothenburg, Link€oping, Umea and Uppsala-€Orebro
[16].
Vital status and socioeconomic index
The Total Population Register provided information
on date of death and migration. A six-category socio-
economic index entry (manual workers, non-manual
workers, professionals, self-employed, farmers and
others) was based on occupation identiﬁed from the
census nearest in time to study entry. All data were
linked using the unique personal identity number
issued to all Swedish residents [17].
Study population
From amongst the original 20 543 with MS and
204 161 without, 1047 and 10 428 observations were
excluded, respectively, due to a cancer diagnosis
before the entry date. One member of the MS cohort
and six members without MS were excluded due to
inaccurate data. In total, 19 364 with MS and 192 519
without the diagnosis were included to the study. A
total of 1768 MS patients and 24 965 from the general
population cohort had a primary cancer diagnosis
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after entry. Benign tumours were not considered in
estimation of mortality risk after cancer (333 with MS
and 3739 without MS). Cancer diagnoses recorded
after death or based on autopsy ﬁndings were not
included in the analysis, for 98 subjects from the MS
cohort and 878 from the general population cohort.
The number of person-years provided by subjects was
233 317 for the MS cohort and 2 664 450 for the gen-
eral population cohort.
Ethical permission
Karolinska Institutet regional ethics committee
approved this study.
Statistical analysis
Poisson regression was used to estimate relative risks
and 95% conﬁdence intervals for mortality after diag-
nosis of cancer. The relative risks were reported as
unadjusted and as adjusted. The adjustment was for
follow-up duration, year at entry, sex, regional cancer
centre (six cancer centres) and socioeconomic index.
The logarithm of accumulated person-years served as
the oﬀset variable. Attained age was the underlying
time scale.
Follow-up time was started at study entry and was
to the ﬁrst cancer date, emigration, death or 31
December 2005, whichever occurred ﬁrst. Follow-up
time for subjects with a diagnosis of cancer was split
as they were moved to the cohort with cancer risk
from the date of their ﬁrst cancer diagnosis and fol-
lowed until date of second cancer, emigration, death
or 31 December 2005, whichever occurred ﬁrst. The
association of cancer with all-cause mortality was ﬁrst
assessed in the MS and general population cohorts
separately. Then the cohorts were combined for multi-
plicative interaction testing. The interaction of MS
with cancer was adjusted for main eﬀects (MS and
cancer) as well as the other measures.
The analyses were for all cancer types combined
and separately for more speciﬁc diagnoses (Index 1).
Brain tumour diagnoses were only included in overall
risk estimation, as a recent study using the same mate-
rial to examine mortality risk for brain tumour was
published in 2013 [12].
Sensitivity analysis
To examine whether the results may be inﬂuenced by
changes in treatment, including immunomodulatory
therapy, the follow-up period was truncated to before
1996 and from this time onwards, as the ﬁrst of the
more recent therapies, interferon-b, was introduced in
Sweden in 1996 [18].
An analysis was performed limiting subjects with
MS to those included in the SMSreg, to ensure a high
diagnostic accuracy for MS [1].
All tests were two-sided and P < 0.05 and 95% conﬁ-
dence intervals not including 1.00 were considered sta-
tistically signiﬁcant. Statistical analysis was conducted
using Stata/MP statistical software, version 11.2 (Stata-
Corp, College Station, TX, USA).
Results
Subject characteristics
There were 211 883 subjects with full data for analysis
(MS without cancer 19 364, MS with cancer 1768,
general population without cancer 190 695 and gen-
eral population with cancer 24 965). Some 9.1% of
Table 1 Characteristics of the study subjects
Multiple sclerosis cohort General population cohort
All (%) Subjects with cancer (%) All (%) Subjects with cancer (%)
N 19 364 1768 192 519 24 965
Female, % 12 428 (63.7) 1199 (67.82) 123 256 (63.6) 15 759 (12.79)
Age at MS diagnosis/entry
≤20 3429 (17.7) 155 (9.8) 34 202 (17.1) 1822 (7.3)
21–30 4280 (22.1) 268 (15.2) 42 410 (22.1) 3804 (15.2)
31–40 4483 (23.2) 418 (23.6) 44 664 (23.2) 6079 (24.4)
41–50 3739 (19.3) 468 (26.5) 36 856 (19.1) 6660 (26.7)
51–60 2109 (10.9) 302 (17.1) 21 045 (10.9) 4420 (17.7)
61–70 1001 (5.2) 132 (7.5) 10 051 (5.2) 1816 (7.3)
≥71 323 (1.6) 25 (1.3) 3291 (1.7) 464 (1.42)
Mean (SD) 39.8 (15.7) 45.5 (14.2) 39.5 (15.8) 46.0 (14.2)
Mean (SD) age at cancer diagnosis 60.5 (13.4) 63.3 (13.3)
Average follow-up time from entry, years*(SD) 11.9 (9.0) 14.0 (9.5) 13.0 (9.8) 16.5 (9.3)
*Follow-up time was started at study entry and was to the ﬁrst cancer date, emigration, death or 31 December 2005, whichever occurred ﬁrst.
© 2015 EAN
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19 364 MS patients had a cancer diagnosis and the
corresponding proportion in the general population
cohort was 12.9% from amongst 192 519 (Table 1).
Mean age and standard deviation (SD) at entry for
1768 MS patients with cancer (572 male and 958
female) was 45.5 (14.2) years and mean disease
duration was 14.0 (9.5) years. Mean age at cancer
diagnosis (SD) was 60.5 (134) for MS and 63.3
(13.3) in the general population.
All-cause mortality after a primary cancer diagnosis in
individuals with and without multiple sclerosis
All-cause mortality following a cancer diagnosis was
estimated amongst those with and without MS sepa-
rately. Table 2 shows that amongst those with MS the
relative risk (and 95% conﬁdence interval) for mortal-
ity following any cancer diagnosis is 3.06 (2.86–3.27)
and the risk is notably higher in the non-MS cohort,
at 5.73 (5.62–5.85). This lower relative risk of mortal-
ity following cancer amongst the MS cohort compared
with the general population cohort was conﬁrmed by
multiplicative interaction testing (<0.001), when both
cohorts were combined. A similar statistically signiﬁ-
cant lower relative risk of mortality following cancer
in the MS cohort was observed for the cancers of spe-
ciﬁc organ systems, except for the kidney, urinary
organs, endocrine, eye, nose or middle ear, but in
some instances this may have been due to small num-
bers of subjects (Table 2).
Sensitivity analysis included division of the follow-up
period by calendar year to before 1996 and from 1996,
when immunomodulation therapy was recommended
for MS treatment in Sweden. The risk estimates for the
periods before 1996 (the number of events in subjects
with MS was 1542) and from this time (the number of
events in subjects with MS was 226) were broadly simi-
lar and statistically signiﬁcant. The interaction analyses
for these periods produced similar results of 0.50 (0.46–
0.54), P < 0.001, for the earlier period and 0.49 (0.46–
0.53), P < 0.001, for the later.
When subjects with MS were limited to those iden-
tiﬁed using the SMSreg the main ﬁndings were
broadly similar (data not shown).
Discussion
Although a diagnosis of cancer (all types combined)
was associated with a raised relative risk of all-cause
mortality in both the MS and general population
cohorts (well known to be as high as 33%) [19], the
magnitude of risk was lower amongst those with MS.
A similar consistent pattern of lower magnitude risk
of all-cause mortality amongst those with MS was
found across a range of cancer types, with some
exceptions. The results from multiplicative interaction
testing provide more evidence that there is no greater
mortality risk following cancer in MS patients com-
pared with the general population. This suggests that
in the majority of MS patients cancer diagnosis is not
delayed, as this would tend to be associated with a
worse prognosis and a higher mortality risk.
Previous ﬁndings have shown an inverse association
between MS and cancer risk [1–3,20]. The reasons for
this reduced risk are uncertain, but it has been sug-
gested that cancer diagnoses may be missed or delayed
in MS patients, resulting in a form of ‘diagnostic
neglect’ [3]. Other studies have examined cancer-spe-
ciﬁc mortality in MS and also found lower risks for
mortality than in the general population [21] or no dif-
ference with the general population [22]. However, a
direct comparison of cause-speciﬁc mortality between
those with and without MS can be problematic.
On average, the life span of patients with MS is
shorter than that of the general population [23,24].
This excess mortality is due to several causes, includ-
ing a 7.5 times higher risk of suicide [7,23,25]. The
higher risk of mortality from other causes may result
in a lower magnitude relative risk of mortality associ-
ated with cancer (all-cause or cancer speciﬁc), as
observed. This bias was tackled in two ways. First,
our outcome was all-cause mortality to avoid underes-
timation of cancer-speciﬁc mortality. Secondly, inter-
action analysis was performed to assess whether the
diﬀerence in mortality risk following cancer was of
lower magnitude amongst MS patients, even after tak-
ing into account diﬀerences in mortality risk compared
with the general population. The results indicate that,
even after taking these diﬀerences into account, there
was no increased mortality risk following a cancer
diagnosis compared with the general population.
There is even evidence of the possibility that cancer
survival may be better in patients with MS. This is
consistent with the suggestion that cancer diagnoses
are not more frequently delayed in this patient group.
The apparently lower magnitude of increased mor-
tality risk following a cancer diagnosis in MS could
indicate that the lower risk of cancer observed in MS
is a genuine phenomenon rather than a diagnostic
artefact. The reason for such a reduced cancer risk
can only be speculation [1]. Tobacco is a well-known
carcinogen associated with higher all-cause mortality
risk in MS [26]. A lower mortality in MS after a lung
cancer diagnosis was observed, although MS patients
may have given up smoking at an earlier age as it is
also linked with MS risk [27]. Higher body mass index
(BMI) is a risk for some cancers [28], although the
association of BMI with MS is inconsistent, with
© 2015 EAN
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higher BMI associated with an increased risk of onset
[29] but lower BMI after onset [30–32]. There is no
evidence that screening programmes, such as for
breast or prostate cancer, involve greater participation
by MS patients. The hypothesis that MS results in a
greater risk of cancer symptoms being missed was
tested. One interpretation of the ﬁndings is that the
opposite occurs: the frequent medical contact to man-
age MS may result in earlier rather than later detec-
tion of cancer and thus an improved prognosis. This
would also be consistent with a genuinely reduced
cancer risk in MS [1]. It is speculated that cancer pro-
tection might partly result from the increase in sys-
temic autoimmune responses such as against myelin
antigens observed mong patients with MS [1].
The strengths of this study include its representa-
tiveness for MS patients in Sweden and the high level
of precision oﬀered by such large cohorts. The overall
completeness of the cancer register in Sweden is also
high [15], so it is unlikely that an important number
of cancer diagnoses have been missed. Another advan-
tage is that it was possible to compare mortality risk
with a matched sample of the general population,
using interaction testing to take into account diﬀer-
ences in mortality not linked with cancer. It was also
possible to adjust for measures associated with both
cancer and mortality risk, including socioeconomic
index. Possible regional diﬀerences in cancer diagnosis
or survival were taken into account.
The study also has some potential limitations. It is
possible that diﬀerences in cancer case mix between
those with and without MS may inﬂuence the ﬁndings.
Whilst this may be true for some speciﬁc cancer types
[12], the results were consistent across a range of can-
cers, suggesting diﬀerences in case mix are unlikely to
explain the main ﬁndings. Another possibility is that,
rather than some cancer diagnoses being delayed, they
are missed altogether more often amongst MS patients.
Whilst this cannot be disproved, it seems unlikely that
none of these cancer diagnoses would be made at a
later time point as the disease progressed, but prior to
death. It was not possible to examine inﬂuences of
more recently introduced immunomodulatory therapy
as these data were not available from the registers for
the study period. However, the results were similar in
periods before and after introduction of interferon-b1b
in Sweden. It was not possible to identify the speciﬁc
immunological characteristics or environmental expo-
sures that may explain our ﬁndings.
Conclusions
A lower magnitude risk of all-cause mortality following
a cancer diagnosis in MS compared with mortality risk
following a cancer diagnosis in a general population
sample was found, suggesting that cancer diagnoses
tend not to be more delayed in MS patients. This in
turn suggests that cancer is not consistently missed in
this patient group and that the lower cancer risk
reported in MS is not the result of ‘diagnostic neglect’,
thus providing more evidence of a genuinely reduced
cancer risk in MS.
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Appendix
The following ICD codes have been used to
identify cancer diagnosis used in the
analysis.
Type of cancer ICD-7
Digestive cancer (150–159)
Respiratory cancer (160–164)
Breast cancer (170)
Female genital cancer (17, 172, 175)
Male genital cancer (177, 178)
Kidney cancer (180)
Urinary organ cancer excluding kidney (181)
Endocrine cancer (194, 195)
Bone and connective tissue cancer (196, 197)
Blood cancer (200–202, 203, 205)
Skin cancer (190, 191)
Eye, nose, middle ear cancer (160, 192)
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